Loading...
•
Dec 31, 2023
Madrigal Q4 2023 Earnings Report
Madrigal Pharmaceuticals reported Q4 2023 financial results and provided corporate updates.
Key Takeaways
Madrigal Pharmaceuticals reported Q4 2023 operating expenses of $117.2 million, with research and development expenses at $70.6 million and general and administrative expenses at $46.5 million. The company's cash, cash equivalents, and marketable securities totaled $634.1 million as of December 31, 2023.
Mardi C. Dier was appointed as Chief Financial Officer.
Resmetirom is anticipated to become the first medicine approved for NASH with a PDUFA date of March 14, 2024.
Year-end 2023 cash, cash equivalents, and marketable securities were reported at $634 million.
Positive results from the 52-week pivotal Phase 3 MAESTRO-NASH trial were published in the New England Journal of Medicine.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...